Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
8
×
boston top stories
life sciences
national blog main
national top stories
new york blog main
clinical trials
new york top stories
san francisco blog main
alnylam pharmaceuticals
biotech
national
san francisco top stories
boston
cancer
spark therapeutics
amgen
autoimmune diseases
biotech ipos
boulder/denver blog main
boulder/denver top stories
bristol-myers squibb
detroit blog main
detroit top stories
europe blog main
europe top stories
fda
gene therapy
immunotherapy
indiana blog main
indiana top stories
investing
medicare
pfizer
raleigh-durham blog main
raleigh-durham top stories
rna interference
san diego blog main
san diego top stories
seattle blog main
What
market
8
×
drug
medicine
new
patients
data
fda
gene
interference
medicines
payers
rna
science
therapy
advantages
alnylam
aren’t
arrival
bar
benefiting
bio
biotech
boston
bringing
brings
cancer
car
cholesterol
cleared
clears
close
closer
coming
companies
cutting
days
diagnostics
edge
eisai
expect
Language
unset
Current search:
" boston blog main "
×
market
×
@xconomy.com
4 years ago
Two Days, Six IPOs, and $1B Raised for Biotech Research & More
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
5 years ago
MedCo Preps for FDA Filing as Cholesterol Drug Clears Last Two Tests
@xconomy.com
5 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
5 years ago
With Data, Pfizer/Sangamo Step Forward in Hemophilia Gene Therapy Race
@xconomy.com
5 years ago
Laurie Glimcher To Headline Xconomy Keynote Series in Boston in September
@xconomy.com
5 years ago
With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug
@xconomy.com
6 years ago
CAR-T’s Launch, Payers vs. Gene Therapy & Photos From “What’s Hot”